Prelude Therapeutics director granted 38,000 options
Prelude Therapeutics Inc director Martin Babler received a grant of options to buy 38,000 shares of common stock as compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Prelude Therapeutics Inc director Martin Babler received a grant of options to buy 38,000 shares of common stock as compensation. The options have an exercise price of $3.94 per share and expire on June 8, 2036.
The award will fully vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, subject to his continued service. Following this grant, Babler directly holds options for 38,000 underlying common shares.
Insider Trade Summary
Grant/Award: 38,000 shares
Grant/Award
1 txn
Insider
Babler Martin
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) | 38,000 | $0.00 | $0.00 |
Holdings After Transaction:
Director Stock Option (Right to Buy) — 38,000 contracts (Direct)
Footnotes (1)
- F1. The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.
Key Figures
Options granted: 38,000 options
Underlying shares: 38,000 shares
Exercise price: $3.94 per share
+2 more
5 metrics
Options granted
38,000 options
Director stock option grant for common stock
Underlying shares
38,000 shares
Common stock underlying the director stock option
Exercise price
$3.94 per share
Strike price of the granted options
Expiration date
June 8, 2036
Option award expiration
Holdings after grant
38,000 options
Total derivative securities held following transaction
Key Terms
Director Stock Option (Right to Buy), exercise price, expiration date, grant, award, or other acquisition, +1 more
5 terms
Director Stock Option (Right to Buy) financial
"security_title: Director Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 3.9400"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-08T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
annual stockholder meeting financial
"The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting"
An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Prelude Therapeutics (PRLD) report for Martin Babler?
Prelude Therapeutics reported that director Martin Babler received a grant of options for 38,000 shares of common stock. The options are compensation-related, carry a $3.94 exercise price, and give him the right to buy shares at that price before expiration.
What is the exercise price of Martin Babler’s Prelude Therapeutics (PRLD) stock options?
The options granted to director Martin Babler have an exercise price of $3.94 per share. This means he can purchase Prelude Therapeutics common stock at $3.94 per share upon vesting and exercise, regardless of the market price at that time, until the options expire.
When do Martin Babler’s Prelude Therapeutics (PRLD) options vest?
The options will fully vest on the earlier of Prelude Therapeutics’ next annual stockholder meeting or the one-year anniversary of the grant date. Vesting is conditional on Babler continuing to provide service to the company on each applicable vesting date, according to the footnote.
When do the newly granted Prelude Therapeutics (PRLD) options expire?
The granted director stock options expire on June 8, 2036. After this expiration date, any unexercised portion of the 38,000-share option award will lapse, and the right to purchase Prelude Therapeutics common stock at the $3.94 strike price will no longer be available.
How many Prelude Therapeutics (PRLD) options does Martin Babler hold after this grant?
After the grant, Martin Babler holds options for 38,000 underlying shares of Prelude Therapeutics common stock. The Form 4 shows this as his total derivative holdings following the transaction, reflecting the full amount of the newly awarded director stock option grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates